Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests do not require special equipment, are read by eye, have short development times, low cost and can be applied at the Point of Care. Here we describe a quantitative Haemagglutination test (HAT) for the detection of antibodies to the receptor binding domain of the SARS-CoV-2 spike protein. The HAT has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR diagnosed infection. We will supply aliquots of the test reagent sufficient for ten thousand test wells free of charge to qualified research groups anywhere in the world.

Original publication

DOI

10.1038/s41467-021-22045-y

Type

Journal article

Journal

Nature communications

Publication Date

29/03/2021

Volume

12

Addresses

MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford, UK. alain.townsend@imm.ox.ac.uk.

Keywords

Humans, Antibodies, Monoclonal, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Agglutination Tests, Hemagglutination Tests, Sensitivity and Specificity, Polymerase Chain Reaction, Point-of-Care Systems, Spike Glycoprotein, Coronavirus, Seroconversion, COVID-19, SARS-CoV-2, COVID-19 Testing